Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a major worldwide health problem. Recent studies suggest that the gut microbiota influences NAFLD pathogenesis. Here, a murine model of high-fat diet-induced (HFD-induced) NAFLD was used, and the effects of alterations in the gut microbiota on NAFLD were determined. Mice treated with antibiotics or tempol exhibited altered bile acid composition, with a notable increase in conjugated bile acid metabolites that inhibited intestinal farnesoid X receptor (FXR) signaling. Compared with control mice, animals with intestine-specific Fxr disruption had reduced hepatic triglyceride accumulation in response to a HFD. The decrease in hepatic triglyceride accumulation was mainly due to fewer circulating ceramides, which was in part the result of lower expression of ceramide synthesis genes. The reduction of ceramide levels in the ileum and serum in tempol- or antibiotic-treated mice fed a HFD resulted in downregulation of hepatic SREBP1C and decreased de novo lipogenesis. Administration of C16:0 ceramide to antibiotic-treated mice fed a HFD reversed hepatic steatosis. These studies demonstrate that inhibition of an intestinal FXR/ceramide axis mediates gut microbiota-associated NAFLD development, linking the microbiome, nuclear receptor signaling, and NAFLD. This work suggests that inhibition of intestinal FXR is a potential therapeutic target for NAFLD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Hence, treatment with antibiotics ameliorates high-fat-diet-induced NAFLD in mice55.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [55]
In the citing paper
“Conversely, some data also indicate that antagonism of intestinal FXR signaling could improve metabolic parameters in murine models of NAFLD [256,257].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [257]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245
Functional interactions between the gut microbiota and host metabolism
Tremaroli, V., & Bäckhed, F. (2012) · Nature · doi:10.1038/nature11552 · Cited by 4,387
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Mechanisms underlying the resistance to diet-induced obesity in germ-free mice
Bäckhed, F., Manchester, J. K., Semenkovich, C. F., & Gordon, J. I. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605374104 · Cited by 2,615
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Human gut microbiota in obesity and after gastric bypass
Zhang, H., DiBaise, J. K., Zuccolo, A., Kudrna, D., Braidotti, M., Yu, Y., Parameswaran, P., Crowell, M. D., Wing, R., Rittmann, B. E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812600106 · Cited by 1,880
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819 · cited 1×
“FXR, the central sensor and regulator for the biosynthesis and enterohepatic recycling of bile acids, plays a pivotal role in the control of lipid metabolism (42–45).”
Self-citation
Research works printed but not linked: 1
- 10.1172/jci21025 · DOI · Paper page
Cited by
Items 501–600 of 746
Ursodeoxycholic acid acts as an ileal FXR agonist in male mice with hepatic deficiency of FXR
Henry, Z. R., Maliha, S., Basaly, V., Yang, Z., Taylor, R. E., Otersen, K., Meadows, V., Rizzolo, D., Stofan, M., Bhattacharya, A., et al. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100227 · Cited by 12
Self-citationYang, X., Weber, A. A., Mennillo, E., Secrest, P., Chang, M. W., Wong, S., Le, S., Liu, J., Benner, C. W., Karin, M., et al. (2023) · Environmental Health Perspectives · doi:10.1289/ehp12381 · Cited by 12
Liver metabolomics in a mouse model of erythropoietic protoporphyria
Wang, P., Sachar, M., Guo, G. L., Shehu, A. I., Lu, J. L., Zhong, X., & Ma, X. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.06.011 · Cited by 12
Phenotypic effects of dietary stress in combination with a respiratory chain bypass in mice
Dhandapani, P. K., Lyyski, A., Paulin, L. G., Khan, N. A., Suomalainen, A., Auvinen, P., Dufour, É., Szibor, M., & Jacobs, H. T. (2019) · Physiological Reports · doi:10.14814/phy2.14159 · Cited by 12
Metabolic effects of bile acid sequestration: impact on cardiovascular risk factors
Spinelli, V., Chávez‐Talavera, O., Tailleux, A., & Staels, B. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000235 · Cited by 12
Rigamonti, A. E., Dei, M., Caroli, D., Col, A. D., Cella, S. G., Paroni, R. C., & Sartório, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087451 · Cited by 11
Gut microbiota and its role in development of chronic disease and aging
Vesnina, A. D., Frolova, A. S., Chekushkina, D., Milentyeva, I., Luzyanin, S., & Aksenova, L. (2025) · Foods and raw materials · doi:10.21603/2308-4057-2026-1-668 · Cited by 11
Wang, Y., Deng, D., Mai, M., Song, W., Yuan, Q., Xie, Y., Mo, B., & Guo, H. (2025) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2025.106812 · Cited by 11
Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease
Wang, J., Yang, N., & Xu, Y. (2024) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x24500137 · Cited by 11
Li, C., Cao, J., Chen, Z., Su, Z., Bao, H., Li, X., Liu, L., Xiao, Z., Duan, J., Zhou, T., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176582 · Cited by 11
Role of sirtuins in obesity and osteoporosis: molecular mechanisms and therapeutic targets
Du, Y., Huo, Y., Yang, Y., Lin, P., Liu, W., Wang, Z., Zeng, W., Li, J., Liang, Z., Yuan, C., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-024-02025-7 · Cited by 11
Amini‐Nik, S., Sadri, A.-R., Diao, L., Belo, C., & Jeschke, M. G. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0118-x · Cited by 11
Multiplatform Physiologic and Metabolic Phenotyping Reveals Microbial Toxicity
Cai, J., Nichols, R. G., Koo, I., Kalikow, Z. A., Zhang, L., Tian, Y., Zhang, J., Smith, P. B. W., & Patterson, A. D. (2018) · mSystems · doi:10.1128/msystems.00123-18 · Cited by 11
Self-citationBile Acids in Control of the Gut-Liver-Axis
Hild, B., Heinzow, H. S., Schmidt, H., & Maschmeier, M. (2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1330-9644 · Cited by 11
Omics Approaches To Probe Microbiota and Drug Metabolism Interactions
Nichols, R. G., Hume, N. E., Smith, P. B. W., Peters, J. M., & Patterson, A. D. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00236 · Cited by 12
Self-citationFood and Gut Microbiota-Derived Metabolites in Nonalcoholic Fatty Liver Disease
Jeong, M. K., Min, B. H., Choi, Y. R., Hyun, J. Y., Park, H., Eom, J. A., Won, S. M., Jeong, J., Oh, K., Gupta, H., et al. (2022) · Foods · doi:10.3390/foods11172703 · Cited by 11
Wang, W., Liao, L., Liang, H., Huang, P., Li, Q., Zhuang, B., Xie, C., Mo, X., Deng, X., Li, J., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.187083 · Cited by 10
Self-citationUpdate on lipid species and paediatric nonalcoholic fatty liver disease
Mann, J. P., Feldstein, A. E., & Nobili, V. (2016) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000346 · Cited by 10
Yang, D., Wei, X., Zhang, B., Zhu, R., Hu, H., Fan, X., Du, H., Chen, X., Zhang, Z., Zhao, M., et al. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113440 · Cited by 10
Finamore, C., Festa, C., Fiorillo, B., Leva, F. S. D., Roselli, R., Marchianò, S., Biagioli, M., Spinelli, L., Fiorucci, S., Limongelli, V., et al. (2023) · Molecules · doi:10.3390/molecules28062840 · Cited by 10
Li, Y., Liu, X., Sun, X., Li, H., Wang, S., Tian, W., Chen, X., Zhang, X., Zheng, J., Wang, H., et al. (2024) · Protein & Cell · doi:10.1093/procel/pwae016 · Cited by 10
Self-citationNon-alcoholic Fatty Liver Disease: A Global Public Health Issue
Kaya, E., & Yilmaz, Y. N. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_24 · Cited by 10
Nakatsu, G. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15715 · Cited by 10
Liao, L., Liu, Z., Liu, L., Huang, C., Li, Y., Mao, C., Xu, R., Liu, H., Liu, C., Peng, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57330-7 · Cited by 9
Guo, J., Huang, S., Yi, Q., Liu, N., Cui, T., Duan, S., Chen, J., Li, J., Li, J., Wang, L., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c02347 · Cited by 9
Du, J., Cao, L., Gao, J., Nie, Z., Li, Q., Sun, Y., Shao, N., Hu, J., Zhou, L., Yin, G., et al. (2024) · Aquaculture Reports · doi:10.1016/j.aqrep.2024.101994 · Cited by 9
An insoluble cellulose nanofiber with robust expansion capacity protects against obesity
Yu, J. G., Gao, M., Wang, L., Guo, X., Liu, X., Sheng, M., Cheng, S., Guo, Y., Wang, J., Zhao, C., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134401 · Cited by 9
Self-citationFXR Friend-ChIPs in the Enterohepatic System
Meadows, V., Yang, Z., Basaly, V., & Guo, G. L. (2023) · Seminars in Liver Disease · doi:10.1055/a-2128-5538 · Cited by 9
Intestinal farnesoid X receptor puts a fresh coat of wax on fatty liver
Tuominen, I., & Beaven, S. W. (2015) · Hepatology · doi:10.1002/hep.27910 · Cited by 9
Shyng, S. (2017) · Diabetes · doi:10.2337/dbi16-0066 · Cited by 9
The gut’s feeling on bile acid signaling in NAFLD
Chiang, J. Y. L. (2018) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2018.01.02 · Cited by 9
Adipose ADM2 ameliorates NAFLD via promotion of ceramide catabolism
Wang, P., Zhang, S., Dong, Y., Zeng, G., Liu, H., Wang, X., Jiang, C., & Li, Y. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.09.010 · Cited by 8
Self-citationInsights Into Intestinal Flora in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Xin, Z., Wang, Z., & Chu, M. (2025) · The FASEB Journal · doi:10.1096/fj.202403293rr · Cited by 8
Yang, J., van Dijk, T. H., Koehorst, M., Havinga, R., de Boer, J. F., Kuipers, F., & van Zutphen, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044132 · Cited by 8
Ma, C., Wang, C., Zhang, Y., Zhou, H., & Li, Y. (2021) · Current Molecular Pharmacology · doi:10.2174/1874467215666211217120448 · Cited by 8
Mitsinikos, T., Chac, D., Schillingford, N., & DePaolo, R. W. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1792256 · Cited by 8
Part III: Steroid Hormone Receptors and Signal Transduction Processes
Klinge, C. M. (2016) · Endocrinology · doi:10.1007/978-3-319-27318-1_9-1 · Cited by 8
Gonzalez, F. J., & Xia, Y. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.10.046 · Cited by 8
Self-citationZhang, Z., Xie, L., Lin, X., He, J., Xie, Y., Li, J., Zhuang, X., Tang, L., Xie, R., Wu, Q., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08403-2 · Cited by 7
Lu, F., Ju, S., Yi, Y., Liu, J., Yang, C., Li, M., Zhou, H., & Yang, B. (2025) · Food Frontiers · doi:10.1002/fft2.70120 · Cited by 7
Dhiman, A., Shah, Y., Chaudhary, U., & Garkhal, K. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00145 · Cited by 7
Gut microbial bile salt hydrolase as a metabolic gatekeeper in digestive homeostasis and disease
Chu, H., Song, X., Liu, C., Ma, T., & Cui, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1870619 · Cited by 7
Wang, J., Zheng, D., Ge, K., Huang, F., Yang, L., Zheng, X., Jia, W. P., & Zhao, A. (2024) · Food Frontiers · doi:10.1002/fft2.394 · Cited by 7
Deletion of hepatic FXR leads to more severe MASH development in female mice.
Henry, Z. R., Armstrong, L. E., Maliha, S., Jia, X., Gao, S., Taylor, R. E., Basaly, V., Otersen, K., Yang, Z., Rizzolo, D., et al. (2025) · PubMed Central · doi:10.1097/hc9.0000000000000693 · Cited by 7
Rol de la microbiota intestinal en el desarrollo del hígado graso no alcohólico
Tumani, M. F., Tapia, G., Aguirre, C. A., Obregón, A. M., & Pettinelli, P. (2021) · Revista médica de Chile · doi:10.4067/s0034-98872021000400570 · Cited by 7
Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer
Wang, K., Wei, Y., Xu, R., Li, Y., & Mao, C. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-0394-6_11 · Cited by 7
Du, Y., Wang, G., Yu, E., Zhang, W., & Tian, J. (2024) · Aquaculture Reports · doi:10.1016/j.aqrep.2024.102337 · Cited by 7
Pathogenic or Therapeutic: The Mediating Role of Gut Microbiota in Non-Communicable Diseases
Bu, F., Yao, X., Lü, Z., Yuan, X., Chen, C., Li, L., Li, Y., Jiang, F., Zhu, L., Shi, G., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.906349 · Cited by 7
Gabdulkhakova, A., Krutsenko, Y., Zhu, J., Liu, S., Poddar, M., Singh, S., Ma, X., Nejak‐Bowen, K. N., Monga, S. P., & Molina, L. M. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000220 · Cited by 7
Whang, E. C., Liu, Y., Kageyama, S., Woo, S., Yang, J., Lee, R., Li, Z., Ji, H., Chen, Y., & Kupiec‐Weglinski, J. W. (2019) · Obesity Surgery · doi:10.1007/s11695-019-03860-1 · Cited by 7
Chronic Liver Disease – What’s New?
Effandie, E., & Gupte, G. L. (2023) · The Indian Journal of Pediatrics · doi:10.1007/s12098-023-04819-y · Cited by 6
Wang, Y., Xing, X., He, Y., Zhang, Y., Ma, Y., Nan, B., Xia, L., Wang, Y., & Liu, J. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250305 · Cited by 6
Li, Y., Jiao, T., Cheng, X., Liu, L., Zhang, M., Li, J., Wang, J., Hu, S., Li, C., Yu, T., et al. (2025) · Life Metabolism · doi:10.1093/lifemeta/loaf004 · Cited by 6
Self-citationYokoyama, Y., Takashina, Y., Morel, J., Taworntawat, T., Kitamura, N., Nagano, U., Tanigaki, T., Nakamura, A., Miyazaki, T., Taoka, H., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112603 · Cited by 6
Ma, Y., Ke, J., Wang, Y., Zhou, Y., Gao, X., Wang, X., & Shen, Q. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1601867 · Cited by 6
Wang, Y., Chen, Y., Cong, Y.-X., Wang, Y.-P., Liu, P., Du, Y.-P., Zhang, J., Wang, X.-C., Xu, T., Sinclair, A. J., et al. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.110136 · Cited by 6
Bile acids as gatekeepers: Orchestrating gut-liver axis for metabolic and immune balance
Chen, Q., Xin, L. I. U., & Jiang, Z.-H. (2026) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2026.01.001 · Cited by 6
Molecular Dialogues in the Mitochondria–Microbiome Crosstalk: Metabolites, Signaling, and Immunity
Tenchov, R. (2026) · Comprehensive physiology · doi:10.1002/cph4.70164 · Cited by 6
Iguchi, Y., Yamashita, Y., Gohda, K., Oda, K., Fujimori, K., Sera, Y., Imanaka, T., Yamaguchi, M., Une, M., & Teno, N. (2024) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b24-00311 · Cited by 6
The rationale for the aggressive progression of MASLD in patients with type 2 diabetes
Fernández‐Garibay, V. M., & Chávez-Tapia, N. C. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101778 · Cited by 6
Pilihan Tatalaksana Penyakit Perlemakan Hati Non-Alkohol (Non-Alcoholic Fatty Liver Disease/ NAFLD)
Setiawan, S. I., & Kurniawan, J. (2021) · Cermin Dunia Kedokteran · doi:10.55175/cdk.v48i3.54 · Cited by 6
Obesity induced Ext1 reduction mediates the occurrence of NAFLD
Wang, M., Li, B., Qin, F., Ye, J., & Jin, L. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.12.017 · Cited by 6
Luo, Z., Niu, M., Gong, S., Wu, G., Wang, T., Wang, F., Wei, G., He, Z., Jiang, Y., & Chen, P. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000915 · Cited by 6
Beyond Farnesoid X receptor to target new therapies for NAFLD
Liu, X., & Green, R. M. (2017) · Hepatology · doi:10.1002/hep.29411 · Cited by 6
Wang, J., Gao, J., Zhang, Q., Lu, J., Yang, Y., Cai, X., Dong, H., & Lu, L. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.17017 · Cited by 5
Wang, Y., Zhou, Z., Hao, H., & Cao, L. (2025) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(25)60909-5 · Cited by 6
Paraiso, I. L., Magaña, A. A., Alexiev, A., Sharpton, T. J., Maier, C. S., Kioussi, C., & Stevens, J. F. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331040 · Cited by 6
HBOT alleviates diet-induced MASH by reprograming gut microbiota and liver metabolism in mice
Chen, L., Xu, S., Zhou, Q., Zhao, T., Zhao, Y., Chen, X., Zhu, W., Ding, J., Zheng, H., Jiang, M., et al. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.05.420 · Cited by 5
Hyocholic acid: A novel therapeutic strategy for metabolic syndrome
Rong, B., Zhang, Q., Zhang, X., Zhang, N., Shen, Z., Pang, Y., Lin, X. K., Liu, D., & Yang, X. (2024) · The Innovation Life · doi:10.59717/j.xinn-life.2024.100093 · Cited by 5
A method for quantifying hepatic and intestinal ceramides on mice by UPLC-MS/MS
Ge, K., Zheng, D., Wang, J., Jia, W. P., & Zhao, A. (2022) · Analytical Biochemistry · doi:10.1016/j.ab.2022.114982 · Cited by 5
Glycyrrhetic Acid Derivative TY501 Protects Against Lithocholic Acid–Induced Cholestasis
Zheng, X., Zhu, S., Zhou, Z., Liu, W., & Xu, W. (2017) · Drug Research · doi:10.1055/s-0043-122222 · Cited by 5
Liang, X., Zhang, Y., Xie, W., Xiong, J., Lin, S., Wen, Y., Cao, Y., Yu, S., Wang, K., Deng, J., et al. (2026) · Nature Microbiology · doi:10.1038/s41564-026-02381-9 · Cited by 4
Self-citationLiu, J., Lian, G., Wang, T., Ma, Y., Zhou, J., Jiang, C., & Yin, Y. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.07.020 · Cited by 4
Self-citationZhang, C., Sui, Y., Liu, S., & Yang, M. J. (2023) · Exploration of Digestive Diseases · doi:10.37349/edd.2023.00029 · Cited by 4
Cong, S., Wang, S., Qiao, Y., Gu, S., Susu, L., Chai, X., & Yongsheng, Z. (2023) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.460 · Cited by 4
Srikanth, P., Shaik, K. M., Patibandla, V., Kumar, D., & Nandi, S. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101425 · Cited by 3
Integrating bile acid metabolism into precision nutrition strategies for improved swine performance
Li, S., He, Y., Shaoyong, W., Wang, Y., & Jin, M. (2025) · Animal nutrition · doi:10.1016/j.aninu.2025.05.013 · Cited by 3
Fu, C., Li, T., Hao, Y., Lin, Y., Qiu, Y., Jia, Y., Yang, J., Liu, B., Hua, D., Wang, C., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06618-w · Cited by 3
Bi, Z., Chang, X., Zhu, S., Fu, S., Zhang, Y., Wang, T., Wang, F., Zhuang, H., & Hua, Z. (2026) · Science Advances · doi:10.1126/sciadv.adz2892 · Cited by 3
Cuevas‐Sierra, A., Higuera‐Gómez, A., de Cuevillas, B., Amigó, N., Martínez‐Urbistondo, M., Castejón, R., Vargas, J. A., & Martinez, J. A. (2026) · Scientific Reports · doi:10.1038/s41598-026-36024-0 · Cited by 4
Shao, J., Zhao, D., Xia, Y., Wang, G., Song, X., Yang, Y., Xiong, Z., & Ai, L. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.02.048 · Cited by 4
Paneth cell: The missing link between obesity, MASH and portal hypertension
Kumar, M. S. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102259 · Cited by 3
Diabetes-induced depression: unravelling the role of gut dysbiosis
Sharma, V. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01643-3 · Cited by 3
Gut Microbiota and Host Nuclear Receptors Signalling
Ranhotra, H. S. (2017) · Nuclear Receptor Research · doi:10.11131/2017/101316 · Cited by 3
Yang, H., & Park, C. (2016) · The Korean Journal of Obesity · doi:10.7570/kjo.2016.25.4.167 · Cited by 3
Chen, Z., Watanabe, S., Nishidono, Y., & Tanaka, K. (2020) · Traditional & Kampo Medicine · doi:10.1002/tkm2.1254 · Cited by 3
Schneider, K. M., & Trautwein, C. (2020) · Wiener klinisches Magazin · doi:10.1007/s00740-020-00353-1 · Cited by 3
Lazăr, V., Vasilescu, I.-M., Holban, A. M., & Chifiriuc, M. C. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160608-00191 · Cited by 3
Mifflin, R., Park, J. E., Lee, M., Jena, P. K., Wan, Y. Y., Barton, H. A., Aghayev, M., Kasumov, T., Li, L., Wang, X., et al. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100469 · Cited by 3
Self-citationCheng, Z., Liu, T.-M., Ren, P.-F., Chen, C., Wang, Y., Dai, Y., & Zhang, X. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i31.4328 · Cited by 3
The role of intestinal microbiome in the progression of non-alcoholic fatty liver disease
Fadieienko, G. D., Gridnyev, O., Cherelyuk, N., & Kurinna, O. G. (2019) · Modern Gastroenterology · doi:10.30978/mg-2019-4-92 · Cited by 3
A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease
Mehal, W. Z., & Schwabe, R. F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.035 · Cited by 3
Joshi, D., Chauhan, K., Oberoi, H. S., Kumar, D., & Taneja, N. K. (2026) · Discover Biotechnology · doi:10.1007/s44340-026-00053-2 · Cited by 2
He, Y., Tan, J., Liu, J., Zhong, R., Jiang, L., & Zhao, Y. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108288 · Cited by 2
Acierno, C., Caturano, A., Barletta, F., Rinaldi, L., Sasso, F. C., Adinolfi, L. E., & Nevola, R. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1881697 · Cited by 2
The Postprandial Chronobiome in Interorgan Glucose Homeostasis
Božić, J., Šantić, R., & Kumrić, M. (2026) · Comprehensive physiology · doi:10.1002/cph4.70236 · Cited by 2
Liu, J., & Wu, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1879097 · Cited by 2
Li, Y., Dai, C., Yang, H., Zeng, H., Ruan, Y., Dai, M., Hao, J., Wang, L., Yan, X., & Ji, F. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16687 · Cited by 3
Bisson, W. H., Amedei, A., Memeo, L., Forte, S., & Felsher, D. W. (2017) · John Wiley & Sons, Inc. eBooks · doi:10.1002/9781119023647.ch14 · Cited by 2
Yiğit, A., & Samur, G. (2022) · Current Nutrition & Food Science · doi:10.2174/1573401318666220520100202 · Cited by 2
Metadata
- Authors
- Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z.-Z., Takahashi, S., Tanaka, N., Desai, D., Amin, S. G., Albert, I., Patterson, A. D., & Gonzalez, F. J.
- Affiliations
- National Institutes of Health (US)
- Pennsylvania State University (US)
- Corresponding author
- Patterson, Andrew D.
- Gonzalez, Frank J.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-12-15
- Volume
- 125
- Issue
- 1
- Pages
- 386-402
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4382255
- OpenAlex
- W2124025733
- Cited by
- 693
- References
- 68
- Citations by year
- 2026: 43 · 2025: 52 · 2024: 52 · 2023: 61 · 2022: 76 · 2021: 84 · 2020: 70 · 2019: 63 · 2018: 58 · 2017: 61 · 2016: 46 · 2015: 26
- FWCI
- 33.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Environmental Health Sciences (R01ES022186, ES022186)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- non-alcoholic fatty liver disease, gut microbiota, bile acids, bile acid conjugates, ceramide, ceramide synthesis, SREBP-1c, de novo lipogenesis, hepatic steatosis, high-fat diet, antibiotic therapy, tempol, nuclear receptor signaling, therapeutic target
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Anti-Bacterial Agents, Bile Acids and Salts, Cecum, Gene Expression Regulation, Humans, Ileum, Liver, Male, Mice, Inbred C57BL, Mice, Transgenic, Gene Expression, Receptors, Cytoplasmic and Nuclear, Lipid Metabolism, Metabolic Networks and Pathways, Diet, High-Fat, Mitochondrial Dynamics, Microbiota, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.